SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending as MSCI has decided to maintain Digital Asset Treasury Companies, including MSTR, in its indexes, alleviating a major overhang that had previously weighed on the stock. This news is fueling a strong bullish sentiment within the community, with many anticipating a significant short squeeze and further upside as Bitcoin's price shows strength.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is currently trending as heightened geopolitical focus on Greenland's strategic rare earth deposits, fueled by U.S. administration commentary, drives conversation. The community is actively discussing the potential for government investment and partnerships to secure a Western-aligned supply chain, with attention on the company's Tanbreez project and upcoming business updates. This surge reflects broader market interest in critical minerals and reducing reliance on key producing nations for essential resources.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing an explosive surge, fueled by strong investor interest in memory and storage solutions essential for burgeoning AI infrastructure. The community is hotly debating whether current valuations are sustainable or if these companies should be re-rated given the unprecedented AI-driven demand.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences is trending due to widespread reports of Eli Lilly nearing a multi-billion dollar acquisition, immediately sparking intense market speculation. This potential buyout highlights the strategic value of Ventyx's NLRP3 inhibitor pipeline, with the community actively discussing a possible bidding war among major pharmaceutical companies for its promising applications in chronic inflammatory, cardiometabolic, and neurodegenerative diseases. Many investors see Ventyx's assets as a crucial complementary class to the thriving GLP-1 market, also fueling strong short squeeze sentiment.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid intense community speculation surrounding imminent government contract announcements, especially concerning its secure AI capabilities for defense and potential involvement in TSA modernization. This optimism is fueled by the company's recent strategic debt reduction and the completion of its Ask Sage acquisition, significantly strengthening its financial position and market offerings.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is experiencing a significant uplift following news of an $880 million data center deal in Israel and plans to be an early adopter of NVIDIA's Vera Rubin NVL72 platform. The community is actively discussing this as a major catalyst, fueling optimism for substantial price recovery and long-term growth within the burgeoning AI infrastructure sector, despite the stock's noted volatility.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab (RKLB) is trending on the back of its significant pivot to an end-to-end national security space partner, highlighted by recent major U.S. and U.K. defense contracts totaling over a billion dollars. The community is discussing strong institutional interest and eagerly awaiting the Neutron rocket's debut, with many seeing substantial long-term potential in the expanding space sector, while some also raise questions about its current valuation.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending amid significant community excitement over increasing trading volume and technical breakouts, fueled by widespread anticipation for its 2026 developments. Discussions highlight its strategic focus on decentralized AI, DePIN, and secure data monetization via its Layer-2 network, alongside its strong regulatory standing in Japan, though some observers remain cautious regarding historical volatility.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis is trending due to highly positive Phase 3 clinical trial results for its oral TYK2 inhibitor, envudeucitinib, in plaque psoriasis, which demonstrated strong skin clearance and a favorable safety profile. This breakthrough has prompted significant analyst price target increases and robust community discussion, with many anticipating the drug to be a best-in-class contender in a lucrative market. While some debate potential future offerings, the company's solid cash position and pipeline for other immune-mediated diseases like lupus are fueling bullish sentiment among traders.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is trending due to its recent business combination and debut on NASDAQ, sparking extreme volatility and multiple trading halts. The community is actively discussing its 'low float' characteristics, with many celebrating rapid short-term gains while others struggle to enter positions amidst the aggressive price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OKYO Pharma CEO Gary Jacob Transitions To CDO; Appoints Robert Dempsey As CEO

(RTTNews) - OKYO Pharma Ltd. (OKYO), on Monday, said it has appointed Robert Dempsey as Chief Executive Officer, effective immediately...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling...

OKYO Pharma (NASDAQ:OKYO) Stock Rating Upgraded by B. Riley

B. Riley raised OKYO Pharma to a "strong-buy" rating and set a $5.00 target price for the company in a research report on Monday...

OKYO Pharma (NASDAQ:OKYO) Shares Down 4.5% - Time to Sell?

OKYO Pharma (NASDAQ:OKYO) Shares Down 4.5% - Here's Why...

Shares of OKYO Pharma (OKYO) jumped 8% on Monday morning after the company said that it is now planning to advance to a multiple-ascending-dose (MAD) clinical trial for its lead drug candidate Urcosimod.Urcosimod is being developed to treat neuropathic corneal pain (NCP), a condition that causes severe pain and sensitivity of the eyes, face, or head, and is thought to result from nerve damage to the cornea combined with inflammation.In July, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://okyopharma.com/okyo-pharma-announces-registration-pathway-with-100-patient-multi-center-clinical-trial-of-urcosimod-in-neuropathic-corneal-pain/">announced</a> data from a mid-stage trial of Urcosimod in 17 NCP patients. After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% Urcosimod showed greater than 80% reduction in neuropathic corneal pain in that study, as measured by visual analog scale.Okyo said on Monday that it is now focused on advancing to a multiple-ascending-dose (MAD) clinical trial designed to enroll approximately 100 NCP patients across several U.S. clinical sites. The purpose of the trial is to identify the optimal registration dose for Urcosimod for future late-stage trials and to develop an understanding of the drug’s characteristics.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OKYO">OKYO stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:578/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_1_09_35_PM_png_4bfce5981c.webp" alt="OKYO's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Sept. 22, 2025 | Source: Stocktwits" width="578" height="57"><figcaption>OKYO's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Sept. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that they now see a “clear route forward.”<stembedurl>https://stocktwits.com/rp6577/message/629485633</stembedurl>The company said that it expects data from this new trial in 2026, and negotiations are underway with several clinical sites in the U.S. Okyo continues to progress toward a meeting with the U.S. Food and Drug Administration (FDA) to discuss requirements for an approvable drug to treat NCP and to define the primary endpoint required for potential registration, it said.“Our next &nbsp;MAD clinical trial is designed to give us the data needed to define an optimal registration pathway for urcosimod, and we are moving rapidly to initiate this study. With Fast-Track designation in place and a constructive engagement anticipated with FDA, we are well-positioned to bring this novel therapy closer to patients in need,” said CEO Gary S Jacob.OKYO stock is up 85% this year and approximately 112% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-awarded-with-yet-another-price-target-hike-after-waymo-partnership/chDQu3aR32s">Lyft Awarded With Yet Another Price Target Hike After Waymo Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug

Okyo announced on Monday that it is now focused on advancing to a multiple-ascending-dose clinical trial, designed to enroll approximately 100 patients with neuropathic corneal pain across several U.S. clinical sites.

Equity

Okyo announced on Monday that it is now focused on advancing to a multiple-ascending-dose clinical trial, designed to enroll approximately 100 patients with neuropathic corneal pain across several U.S. clinical sites.


OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited - Ordinary Shares - New

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

Current Price	$2.12
Prev Close	$2.40
Open	$2.46
Dividend Yield	0.00%
50-Day Moving Average	$2.19
Beta	0.72
Avg. Volume	128,737.41
PE Ratio	-17.63

52-Week High	$3.35
52-Week Low	$0.9016
Market Capitalization	$90.27M
EPS (Annual)	-$0.1192
Price to Book	-15.58
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

OKYO
Pharma Limited

Feed

News

Sentiment

Fundamentals

Info

Latest OKYO News

OKYOPharma Limited